V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330003611 | 330001839 | null | 24.2 | Neo-adjuvant (N) | 2017-12-06 | 2017-12-07 | EW EuroEwing 99 : VIDE | N | N | 330013247 | EURO-EWING |
| 330003612 | 330006991 | null | null | Curative (C) | 2013-04-08 | 2013-05-11 | EURAMOS TRIAL | N | N | 330013248 | EURAMOS TRIAL |
| 330003613 | 330001840 | 1.68 | 68.3 | Palliative (P) | 2016-01-13 | 2016-01-21 | CAP | N | null | 330013249 | CAP |
| 330003614 | 330006992 | 1.62 | 66 | Palliative (P) | 2013-04-14 | 2013-04-16 | EURO-EWING | 2 | N | 330013250 | EURO-EWING |
| 330003615 | 330006992 | 1.52 | 47.9 | Not known (9) | 2017-05-07 | 2017-05-11 | CYCLOPHOSPHAMIDE + RITUXIMAB | N | N | 330013250 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330003616 | 330001841 | 1.74 | 72.5 | null | 2015-03-15 | 2015-04-09 | CETUXIMAB | 02 | N | 330013252 | CETUXIMAB |
| 330003617 | 330001842 | 1.56 | 47.9 | Curative (C) | 2017-12-24 | 2018-01-06 | Cisplatin + Etoposide po | N | N | 330013253 | CISPLATIN + ETOPOSIDE |
| 330003618 | 330001842 | 1.76 | 84.75 | Disease modification (D) | 2015-01-23 | 2015-01-31 | Cyclophosphamide + Dex + Rituximab | N | N | 330013253 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330003619 | 330001842 | 1.79 | 78.9 | Curative (C) | 2015-07-23 | 2015-07-23 | EW EuroEwing 99 : VIDE | 02 | null | 330013253 | EURO-EWING |
| 330003620 | 330001842 | 1.82 | 73 | Disease modification (D) | 2017-02-28 | 2017-02-28 | CYCLOPHOSPHAMIDE + RITUXIMAB | 02 | null | 330013253 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330003621 | 330001842 | 1.66 | 93.1 | Palliative (P) | null | 2017-05-28 | Carboplatin+Fluorouracil 4 or 5 day | null | null | 330013253 | CARBO + FLUOROURACIL |
| 330003622 | 330001843 | 1.73 | 49.2 | Palliative (P) | 2016-12-10 | 2016-12-17 | CYCLOPHOSPHAMIDE + RITUXIMAB | null | N | 330013266 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330003623 | 330001844 | 1.79 | 62.8 | Curative (C) | 2017-11-19 | 2017-11-19 | OST Euramos 1 Closed Trial - AP | N | N | 330013267 | MAP |
| 330003624 | 330001844 | 1.68 | 101.85 | Curative (C) | 2014-08-05 | 2014-08-26 | Cetuximab 7 day (Cycle 1) | N | N | 330013267 | CETUXIMAB |
| 330003625 | 330001844 | null | 74 | Curative (C) | 2016-01-16 | 2016-01-27 | OST Euramos 1 Closed Trial - AP | null | N | 330013267 | MAP |
| 330003626 | 330001844 | 1.64 | 40 | Neo-adjuvant (N) | 2016-06-08 | 2016-06-08 | CAP | N | N | 330013267 | CAP |
| 330003627 | 330001845 | 1.66 | 54 | Neo-adjuvant (N) | 2015-10-03 | 2015-10-03 | Carboplatin+Fluorouracil 4 or 5 day | 2 | N | 330013274 | CARBO + FLUOROURACIL |
| 330003628 | 330001846 | 1.85 | 84 | Neo-adjuvant (N) | 2014-01-27 | 2014-02-11 | Carbo F | N | N | 330013276 | CARBO + FLUOROURACIL |
| 330003629 | 330006995 | 1.73 | 81 | Palliative (P) | 2017-01-03 | 2017-01-03 | Cisplatin + Etoposide po&iv 3 day | 02 | N | 330013277 | CISPLATIN + ETOPOSIDE |
| 330003631 | 330001847 | 1.83 | 83 | Neo-adjuvant (N) | 2013-11-18 | 2014-05-27 | EURAMOS TRIAL | 02 | N | 330013280 | EURAMOS TRIAL |
| 330003632 | 330001848 | 1.74 | 69.6 | null | 2015-05-30 | 2015-05-30 | CVP R | 02 | N | 330013281 | CVP R |
| 330003633 | 330001849 | 1.62 | 42.3 | Palliative (P) | 2017-05-01 | 2017-05-08 | EP 1 2 or 3 day | N | N | 330013282 | CISPLATIN + ETOPOSIDE |
| 330003634 | 330001850 | 1.68 | 78 | Curative (C) | 2013-05-10 | 2013-05-10 | CYCLOPHOSPHAMIDE + RITUXIMAB | 2 | N | 330013284 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330003635 | 330001850 | 1.7 | 90.7 | Curative (C) | 2014-01-27 | 2014-01-27 | Cetuximab + Radiotherapy Load | 02 | null | 330013284 | CETUXIMAB + RT |
| 330003636 | 330001850 | 1.82 | null | Disease modification (D) | 2015-09-14 | 2015-09-16 | Cyclophosphamide + Dex + Rituximab | null | N | 330013284 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330003637 | 330001851 | 0 | 48.3 | Curative (C) | 2017-05-14 | 2017-05-19 | DA 3 + 10 | N | N | 330013288 | DA |
| 330003638 | 330001852 | 1.62 | 87 | Palliative (P) | 2017-02-27 | 2017-03-04 | CARBOPLATIN + GEMCITABINE | N | N | 330013289 | GEMCARBO |
| 330003639 | 330001853 | null | null | Curative (C) | 2015-11-12 | 2015-11-17 | CYCLOPHOSPHAMIDE + RITUXIMAB | null | N | 330013290 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330003640 | 330001854 | null | null | Not known (9) | 2013-10-08 | 2013-10-21 | CVP R | null | N | 330013291 | CVP R |
| 330003641 | 330001855 | 1.79 | null | Neo-adjuvant (N) | 2016-06-14 | 2016-06-14 | Cisplatin + Etoposide po&iv 3 day | N | N | 330013295 | CISPLATIN + ETOPOSIDE |
| 330003642 | 330001855 | 0 | 62.3 | Curative (C) | 2013-05-26 | 2013-05-26 | Cyclophosphamide + Dex + Rituximab | null | null | 330013295 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330003643 | 330009779 | 1.61 | 61 | Neo-adjuvant (N) | 2015-08-24 | 2015-08-26 | EURAMOS TRIAL | 02 | null | 330013300 | EURAMOS TRIAL |
| 330003644 | 330001856 | 1.75 | 53.85 | Neo-adjuvant (N) | 2016-10-31 | 2016-11-08 | EW EuroEwing 2012 Arm A VIDE | null | N | 330013303 | EURO-EWING |
| 330003645 | 330001856 | 1.85 | 76 | Adjuvant (A) | 2016-11-22 | 2016-11-23 | Cyclophosphamide + Dex + Rituximab | 02 | N | 330013303 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330003646 | 330001857 | 1.66 | 66 | Disease modification (D) | 2013-08-13 | 2013-09-10 | CYCLOPHOSPHAMIDE + RITUXIMAB + Dexamethasone | null | null | 330013306 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330003647 | 330006999 | 1.63 | 49.5 | Disease modification (D) | 2017-03-01 | 2017-03-01 | CVP R | N | N | 330013308 | CVP R |
| 330003648 | 330009780 | 1.71 | 55 | Curative (C) | 2015-01-12 | 2015-01-26 | Cetuximab + Radiotherapy Load | 02 | N | 330013309 | CETUXIMAB + RT |
| 330003649 | 330009780 | 1.79 | 81 | Adjuvant (A) | 2013-06-14 | 2013-06-19 | Cisplatin + Etoposide po | 2 | Y | 330013309 | CISPLATIN + ETOPOSIDE |
| 330003650 | 330001858 | 1.75 | 76.7 | Palliative (P) | 2017-01-15 | 2017-01-29 | CISPLATIN + ETOPOSIDE | 02 | N | 330013311 | CISPLATIN + ETOPOSIDE |
| 330003651 | 330001858 | 1.84 | 92 | Neo-adjuvant (N) | 2014-11-30 | 2014-12-02 | EW EuroEwing 99 : VIDE | 02 | null | 330013311 | EURO-EWING |
| 330003652 | 330001859 | null | 69.1 | null | 2015-12-16 | 2015-12-25 | EW EuroEwing 2012 Arm A VIDE | N | N | 330013317 | EURO-EWING |
| 330003653 | 330001859 | 1.6 | 60 | Disease modification (D) | 2013-11-22 | 2013-12-02 | CYCLOPHOSPHAMIDE + RITUXIMAB | N | N | 330013317 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330003654 | 330001859 | 1.59 | 48 | Adjuvant (A) | 2017-09-24 | 2017-10-02 | Cisplatin + Etoposide po&iv 3 day | Y | N | 330013317 | CISPLATIN + ETOPOSIDE |
| 330003655 | 330001860 | 1.57 | 92 | Curative (C) | 2014-12-22 | 2015-01-03 | EURAMOS TRIAL | N | Y | 330013320 | EURAMOS TRIAL |
| 330003656 | 330001860 | 1.86 | 52.2 | Palliative (P) | null | 2016-02-10 | CYCLOPHOSPHAMIDE + RITUXIMAB | N | N | 330013320 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330003657 | 330001861 | 1.62 | null | Palliative (P) | 2014-12-03 | 2015-01-28 | CYCLOPHOSPHAMIDE + RITUXIMAB | N | N | 330013324 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330003658 | 330001861 | 1.46 | 61.6 | null | 2014-03-26 | 2014-03-31 | CVP R | 02 | N | 330013324 | CVP R |
| 330003659 | 330009782 | 1.69 | 80.8 | Neo-adjuvant (N) | 2017-04-15 | 2017-04-22 | Dox + HD Mtx (post PAM) | 02 | N | 330013328 | DOXORUBICIN + HD MTX |
| 330003660 | 330001862 | 1.84 | 102 | Curative (C) | 2016-05-25 | 2016-08-12 | EURAMOS TRIAL | N | Y | 330013329 | EURAMOS TRIAL |
| 330003661 | 330001863 | 1.6 | 84 | Palliative (P) | 2016-03-14 | 2016-03-17 | CISPLATIN + GEMCITABINE | 02 | null | 330013331 | CISPLATIN + GEMCITABINE |